Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: A retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program
Evan A. Stein, Donald G. Vidt, James Shepherd, Valerie A. Cain, Deborah Anzalone, Michael D. CressmanVolume:
221
Year:
2012
Language:
english
DOI:
10.1016/j.atherosclerosis.2011.12.011
File:
PDF, 781 KB
english, 2012